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Early detection and intervention are key principles in clinical medicine and psychiatry. In this issue ofNeuron,
Cabungcal et al. (2014) demonstrate that prophylactic treatment with antioxidants in adolescence prevents
adult deficits in a rat model relevant to schizophrenia.Schizophrenia (SZ) is a heterogeneous
clinical syndrome with typical onset in
late adolescence and early adulthood.
SZ is typically characterized by psychotic
experiences such as hallucinations and
delusions, as well as deficits in emotion,
motivation, and social and cognitive func-
tions. The disease course and outcome
are frequently chronic and devastating.
Thus, this severe psychiatric condition
has been a major subject of study in psy-
chiatry and neuroscience. Although the
onset of SZ occurs, in most cases, after
puberty, many lines of evidence indicate
that the primary risks for the disease
emerge during earlier neurodevelopment
(Insel, 2010).
To overcome the high social burden
of this difficult condition, two contrasting
approaches are currently utilized. Given
that SZ is highly heritable, large-scale
genetic and genomic studies have taken
place, and over 100 genetic risk loci for
the disease have been identified (Schizo-
phrenia Working Group of the Psychiatric
Genomics, 2014). This genetic informa-
tion can be a promising lead to build path-
ophysiological hypotheses that are to be
tested in the near future. In contrast to
such a bottom-up approach focused on
molecular etiology is a ‘‘top-down’’ strat-
egy, in which detailed and multifaceted
phenotypic analyses are undertaken with
patients, ideally in a longitudinal study
design. Such analyses range from clinical
measures such as symptoms and cog-
nition to magnetic resonance imaging
(MRI) measures of brain chemistry and
molecular profiling with specimens ob-
tained from patients via biopsy. Thesetwo approaches are complementary and
mutually beneficial.
Involvement of oxidative stress in the
pathophysiology in SZ has been sug-
gested for over 80 years. Top-down
approaches that include cutting-edge
technology have recently shed light on
this classic hypothesis (Emiliani et al.,
2014). For example, neuronal cells from
SZ patients, such as induced pluripotent
stem cell (iPSC)-derived neural proge-
nitors and olfactory immature neuronal
cells directly obtained from nasal biopsy,
are useful to address the cellular predis-
position to the disease. Discovery-based
approaches, such as microarray gene
expression and quantitative proteomic
mass spectrometry analyses applied to
iPSC-derived neural progenitor cells,
identified abnormal gene expression and
protein levels related to cytoskeletal re-
modeling and oxidative stress in SZ
(Brennand et al., 2014). Genome-wide
profiling of multiple histone methylations
in olfactory neuronal cells also implied
cellular susceptibility to oxidative stress
in SZ (Kano et al., 2013). A recent meta-
analysis of the studies on oxidative stress
in blood samples from SZ patients com-
pared with those from normal controls,
considering the effect of clinical status
and antipsychotic treatment, has also
suggested a role for oxidative stress and
its potential implication as a biomarker in
SZ (Flatow et al., 2013). The next question
is whether such alterations associated
with oxidative stress indeed occur in the
brain in the disease condition. Thus,
direct assessment of this question by
brain imaging, in particular magneticNeuron 83, Sresonance spectroscopy, theoretically al-
lows us to quantitatively measure the
levels of a major antioxidant glutathione
in regions of interest inside the brain.
Note that although we are optimistic
about this strategy, the methodology still
has room for further improvement, and
thus far no consistent conclusion has
been obtained in regard to the levels of
brain glutathione in SZ compared with
normal controls (Emiliani et al., 2014).
There may be alternatives paths to
move this research strategy forward. In
this issue of Neuron, the collaborative
team of Kim Do and Patricio O’Donnell
(Cabungcal et al., 2014) show data from
a rat model with a neonatal ventral hip-
pocampal lesion (Figure 1). This model
shows altered prefrontal maturation,
including in inhibitory interneurons during
adolescence, and displays SZ-relevant
electrophysiological, histological, and
behavioral abnormalities after puberty.
Thus, this model is a useful tool to test
possible developmental pathophysiolog-
ical scenarios, in particular to explore
mechanisms involved in delayed emer-
gence of anomalies driven by devel-
opmental alterations. The collaborative
team assessed whether oxidative stress
during presymptomatic stages causes
adult anomalies (Cabungcal et al., 2014):
this model confirmed excess oxidative
stress in the prefrontal cortex in adulthood
and further narrowed down the cells un-
der stress to be parvalbumin (PV)-positive
interneurons. Juvenile and adolescent
treatment with the antioxidant N-acetyl
cysteine (NAC) prevented the reduction
of prefrontal PV-interneuron activityeptember 3, 2014 ª2014 Elsevier Inc. 991
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Figure 1. Utility of Preclinical Animal Models of Neurodevelopmental Etiopathology in the
Translational Study of Schizophrenia
Animal models can be utilized to address biological questions on the pathological trajectory to full onset of
schizophrenia after puberty. The trajectory from the primary risk beginning in earlier neurodevelopment to
prodromal stages and full onset is illustrated in the gradation from yellow to orange and red. These models
are potentially useful for developing presymptomatic, prophylactic intervention during adolescence,
including those with the antioxidant N-acetyl cysteine (NAC) (depicted in dark green). Therapeutic con-
cepts initially obtained from preclinical models need to be tested in clinical trials in the near future (de-
picted in light green). PPI, prepulse inhibition; MMN, mismatch negativity.
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Previewsobserved in this model, as well as elec-
trophysiological and behavioral deficits
relevant to SZ. Furthermore, adolescent
treatment with the glutathione peroxidase
mimic ebselen also reversed behavioral
deficits in this animal model. This study
has particular significance in translational
medicine, as the effects of these antioxi-
dants in the rodent model were assessed
by mismatch negativity (a component
of the event-related potential to an odd992 Neuron 83, September 3, 2014 ª2014 Elstimulus in a sequence of stimuli) and
prepulse inhibition (an indicator of senso-
rimotor gating), both of which are known
to be abnormal in many patients with
SZ. Therefore the authors suggest that
presymptomatic oxidative stress yields
abnormal adult brain function in a de-
velopmentally compromised brain, high-
lighting redox modulation as a potential
target for early intervention. This conclu-
sion may not be limited to this specificsevier Inc.model, as excess oxidative stress in a
developmental rodent model useful for
SZ has also been reported in a transgenic
animal model in which Disc1, a suscep-
tibility factor for major mental illnesses
with neurodevelopmental functions, is
perturbed (Johnson et al., 2013).
The present study also raises new sci-
entific questions. First, it is still unclear
how a neonatal hippocampal lesion re-
sults in excess oxidative stress in PV inter-
neurons. This specific question is a part of
more general working hypothesis that
presymptomatic oxidative stress during
adolescence may be a common patho-
physiology downstream of multiple etio-
pathologies of SZ. In addition to the
hippocampal lesion and Disc1 models
(Cabungcal et al., 2014; Johnson et al.,
2013), it would be meaningful to re-
address and examine the levels of juvenile
oxidative stress in multiple animal models
that have been classically studied in dif-
ferent contexts as possible models for
SZ. Then we may be able to determine
mechanisms of how diverse disease etio-
pathologies can converge into common
pathways. Second, it is very important to
examine whether and how excess oxida-
tive stress affects deficits in neural cir-
cuitry in the prefrontal cortex relevant
to SZ. The outstanding aims include the
influences of oxidative stress on the
NMDA-type glutamate receptor as well
as characteristics of PV interneurons and
dendritic spines in the pyramidal neurons
(Emiliani et al., 2014; Steullet et al., 2014).
In addition to its preclinical significance,
the present study provides high potential
for translation. It is known that early inter-
vention is associated with better clinical
outcomes in persons with SZ, raising the
hope that treatment during the prodromal
phase of illness could prevent the devel-
opment of a psychotic disorder and thus
reduce risk of chronic symptoms and
disability (Perkins et al., 2005). Under-
standing the mechanism by which dura-
tion of untreated psychosis influences
prognosis may improve treatment strate-
gies. The significance of ‘‘early detection
and early intervention’’ has also been
well appreciated in other medical condi-
tions, such as cancers and cardiovascular
conditions. Supported by this clinical
approach, systematic longitudinal studies
with subjects carrying familial high risk, as
well as a broader group of people with
Neuron
Previewsmore clinically defined at-risk mental sta-
tus, have taken place all over the world
(Keshavan et al., 2011). These studies,
including the North American Prodrome
Longitudinal Study (NAPLS), have aimed
to define markers that predict transition
of such at-risk status (the prodromal
stages) to full onset of the disease. Of
great interest to these considerations are
recent results from the second phase of
NAPLS that have suggested that inflam-
mation, oxidative stress, and dysregula-
tion of hypothalamic-pituitary axes may
be prominently changed in the prodromal
stages of psychosis (Perkins et al., 2014;
Walker et al., 2013). Thus, the present
observations from the hippocampal lesion
rat model are reasonably compatible with
those from the prodromal subjects. The
translational utility of this model (and,
possibly, of other models that display
similar adolescent changes in stress cas-
cades before SZ-relevant behavioral def-
icits, such as the Disc1 transgenic model
as described above) is therefore highly
underscored.
Based on the above observations, we
discuss future perspectives of ‘‘early
detection and early intervention’’ by uti-
lizing both preclinical models and clini-
cal studies in parallel. First, we need to
clinically validate the effectiveness of an-
tioxidants and redox regulators, such as
NAC, in prodromal subjects and early
stages of SZ. An outstanding question
is to determine whether antioxidants
and redox regulators are most effective
by themselves or when administered
together with lower doses of neurolep-
tics. Because antioxidants may have
less-adverse effects compared with
those of neuroleptics, avoiding metabolic
changes and extrapyramidal signs, a
cost-benefit balance of efficacy and
side effects may determine the optimal
treatment strategy. Preclinical models
may also be able to provide useful in-
formation to this question. Second, if weadd antioxidants and redox regulators
into the treatment strategy, it is important
to establish markers for treatment res-
ponse in biological pathways of oxidative
stress. We expect that such molecular
markers correlate well with clinical indi-
cators, possibly including prepulse inhibi-
tion, mismatch negativity, and working
memory. Interconnected efforts between
preclinical and clinical studies will effi-
ciently answer this question. Third, it
is an interesting question whether oxi-
dative stress may be augmented prior
to relapses and whether treatment with
antioxidants and redox regulators during
remission phases is effective in ‘‘prevent-
ing’’ such deteriorating relapses. Lastly,
intervention strategies may not be limited
to medications. For example, a different
research group, utilizing the same hippo-
campal lesion rat model that was exam-
ined for the antioxidant trials, found
that adolescent cognitive training could
prevent the adult cognitive control im-
pairment (Lee et al., 2012): the early
intervention by cognitive training nor-
malized physiological function of the
brain, enhancing cognition-associated
synchrony of neural oscillations, a mea-
sure of brain function that indexed cogni-
tive ability. Clinically, research to improve
cognitive deficits by training is actively
taking place based on principles of brain
plasticity (Keshavan et al., 2014). These
efforts include new strategies for at-risk
subjects in adolescence and young
adulthood to psychosis, such as com-
puter-associated or mobile phone-asso-
ciated applications for training.
By enhancing translational research
infrastructure in which both preclinical
and clinical studies are meaningfully con-
nected, we are nowcoming to a promising
stage in the exploration of prophylactic
intervention to major mental illnesses.
Combating adolescent oxidative stress
for adult psychosis and schizophrenia is
one of themost promising routes to estab-Neuron 83, Slish prophylactic psychiatry, hopefully in
the near future.
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